DRI Healthcare Trust (TSE:DHT.UN) Stock Price Up 0.1% – Should You Buy?

Shares of DRI Healthcare Trust (TSE:DHT.UN) shot up 0.1% during trading on Thursday. The stock traded as high as C$19.17 and last traded at C$18.77. 48,368 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 53,404 shares. The stock had previously closed at C$18.75.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Stifel Nicolaus raised their target price on shares of DRI Healthcare Trust from C$25.00 to C$26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. National Bank Financial boosted their price target on shares of DRI Healthcare Trust from C$23.50 to C$25.50 and gave the stock an “outperform” rating in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of C$25.60.

DRI Healthcare Trust Stock Performance

The firm has a fifty day simple moving average of C$17.99 and a two-hundred day simple moving average of C$17.34. The firm has a market cap of C$1.06 billion, a PE ratio of 17.81 and a beta of 0.09.

DRI Healthcare Trust Company Profile

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.